Refine
Language
- English (42)
Has Fulltext
- yes (42)
Is part of the Bibliography
- no (42)
Keywords
- SARS-CoV-2 (14)
- COVID-19 (10)
- antiviral therapy (4)
- coronavirus (4)
- Autopsy (2)
- antiviral drugs (2)
- in vitro (2)
- 17‐OH itraconazole (1)
- 2-deoxy-d-glucose (1)
- 2019-nCoV (1)
- ACE inhibitor (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- Acquired resistance (1)
- Acute lymphoblastic leukemia (1)
- Acute myeloid leukemia (1)
- Amizon (1)
- Antigen test (1)
- Bio safety (1)
- Biomarkers (1)
- CD47 (1)
- CNDAC (1)
- COVID 19 (1)
- Caco‐2 cells (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell culture (1)
- Corona virus (1)
- Covid-19 (1)
- DCK (1)
- Darunavir (1)
- EGFR pathway (1)
- ER stress (1)
- Endothelial cells (1)
- FAV00A (1)
- Forensic medicine (1)
- HCC recurrence (1)
- HCV (1)
- HSV (1)
- HSV-1 (1)
- HSV-2 (1)
- Hypertension (1)
- IAP (1)
- IRF-3 (1)
- In vitro (1)
- Inactivation (1)
- Inflammation (1)
- Interferon (1)
- Intrinsic resistance (1)
- Leukemia (1)
- Multivariate analysis (1)
- NF-kB (1)
- Omicron (1)
- Pathology (1)
- Post mortem examination (1)
- Protein-translocation (1)
- Proteomics (1)
- Quarantine (1)
- RNA polymerase (1)
- RT-PCR-detection (1)
- SAMHD1 (1)
- SARS CoV 2 (1)
- SARS coronavirus (1)
- SARS-CoV-2 testing (1)
- SARS‐CoV‐2 (1)
- SIRPalpha (1)
- Sapacitabine (1)
- Stability (1)
- Travel regulations (1)
- VeroE6‐eGFP cells (1)
- Virus trapping (1)
- antiviral (1)
- antiviral agents (1)
- antiviral signaling (1)
- aprotinin (1)
- benfooxythiamine (1)
- cathepsin L inhibitor (1)
- cell barrier integrity (1)
- chelator (1)
- coagulation (1)
- coagulopathy (1)
- direct-acting antivirals (1)
- drug discovery (1)
- drug repurposing (1)
- famotidine (1)
- histamine (1)
- inflammation (1)
- itraconazole (1)
- mesenchymal stromal cells (1)
- molecular dynamics simulation (1)
- monkeypox (1)
- nucleotide analogue (1)
- orthopoxvirus (1)
- oxythiamine (1)
- pentose phosphate pathway (1)
- phenotypic screening; (1)
- poxvirus (1)
- proton pump inhibitors (1)
- qRT-PCR detection (1)
- ribavirin (1)
- severe acute respiratory syndrome coronavirus (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- stem cells (1)
- test protocol (1)
- thrombosis (1)
- toll-like receptor (1)
- transferrin (1)
SARS-CoV-2 is causing the coronavirus disease 2019 (COVID-19) pandemic, for which effective pharmacological therapies are needed. SARS-CoV-2 induces a shift of the host cell metabolism towards glycolysis, and the glycolysis inhibitor 2-deoxy-d-glucose (2DG), which interferes with SARS-CoV-2 infection, is under development for the treatment of COVID-19 patients. The glycolytic pathway generates intermediates that supply the non-oxidative branch of the pentose phosphate pathway (PPP). In this study, the analysis of proteomics data indicated increased transketolase (TKT) levels in SARS-CoV-2-infected cells, suggesting that a role is played by the non-oxidative PPP. In agreement, the TKT inhibitor benfooxythiamine (BOT) inhibited SARS-CoV-2 replication and increased the anti-SARS-CoV-2 activity of 2DG. In conclusion, SARS-CoV-2 infection is associated with changes in the regulation of the PPP. The TKT inhibitor BOT inhibited SARS-CoV-2 replication and increased the activity of the glycolysis inhibitor 2DG. Notably, metabolic drugs like BOT and 2DG may also interfere with COVID-19-associated immunopathology by modifying the metabolism of immune cells in addition to inhibiting SARS-CoV-2 replication. Hence, they may improve COVID-19 therapy outcomes by exerting antiviral and immunomodulatory effects.